A groundbreaking psychedelics research company is working on introducing new treatments for veterans who suffer from PTSD and other neurological conditions. NeuroPharm, under the umbrella of Mydecine, is working on a new, evidence-based medicine to help those who suffer from PTSD, as well as to treat depression anxiety, panic disorders, addiction, cluster headaches, and migraines.
“According to recent, published data, as many as 20 veterans on average commit suicide per day in the U.S. alone, and, to me, this is a heart-breaking staggering statistic that unfortunately is overlooked by so many. We owe everything to our veterans, EMS and frontline personnel, yet the best solutions for their long-term mental health are currently non-existent,” said Mydecine CEO Josh Bartch in a press release. “Aligning ourselves with the amazing team at NeuroPharm affords us the ability to make a positive change. Myself and the rest of the Mydecine team are truly honored to be a part of this effort to finally make a difference, and we are incredibly excited about what we will all accomplish together.”
Scientists and Military Personnel Team Up
What makes NeuroPharm especially remarkable is that the management team is made up of research scientists and military personnel, which allows them to really understand all the nuanced issues of PTSD and the trauma that can be associated with frontline work and military service. They also have research contacts to work with in both North America and the European Union, which will make it easier for them to conduct clinical trials with veterans and make headway in the world of PTSD treatment and veteran health.
So far, the drug combination they are focusing on are microdoses of MDMA and psilocybin. They will conduct some trials this summer, and then plan to follow up with trials in Canada and the United States. These trials will examine how these substances work to make positive changes in behavior and mental wellness for veterans, as well as other folks who need relief.
“Our mission is to develop and bring to market treatments addressing the mental health conditions frequently experienced by veterans, including PTSD, depression and anxiety,” said Colonel (Ret’d) Pucci, CEO of NeuroPharm. “We understand the unique circumstances of the veteran community and are devoted to treating these substantial unmet needs. Our collaborative partnership with Mydecine will accelerate our ability to address the enormous challenge of restoring the overall wellness in the veteran, EMS and frontline personnel communities. We are most pleased to be part of the Mydecine family of companies.”
In addition to facilitating military connections, NeuroPharm will also oversee all areas of their research, including the product life cycle of their medicine, mushroom cultivation, clinical trial execution, and eventually, delivering a product that can be available on the market for PTSD treatment. Overall, the studies will focus on health, wellness, research, development, and therapies to give veterans the tools they need for mental wellness.
While this isn’t the first time MDMA and other psychedelics have been studied to see how they impact PTSD, this large and well-funded study has the potential to help to move things forward within the industry.